The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20/CD19 (LV20.19) CAR T-cell therapy to improve outcomes in patients with relapsed/refractory lymphoma.
 
Fateeha Furqan
No Relationships to Disclose
 
Katie Palen
No Relationships to Disclose
 
Bryon Johnson
No Relationships to Disclose
 
Tyce Kearl
No Relationships to Disclose
 
Peiman Hematti
No Relationships to Disclose
 
Walter L. Longo
No Relationships to Disclose
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Caribou Biosciences; crispr therapeutics; Gamida Cell; Genentech; Genmab; Incyte; Kite/Gilead; MorphoSys; Myeloid Therapeutics; Novartis; Omeros; Puma Biotechnology (I); Sanofi; Seagen; Verastem
Speakers' Bureau - ADC Therapeutics; AstraZeneca; BeiGene; Genzyme; Kite/Gilead
Research Funding - Astellas Pharma; Genzyme; Genzyme; Otsuka; Spectrum Pharmaceuticals; Takeda
 
Timothy S. Fenske
Stock and Other Ownership Interests - Merck
Honoraria - Adaptive Biotechnologies; AstraZeneca; BeiGene; Kite, a Gilead company; MorphoSys; Pharmacyclics; Sanofi; Seagen; SERVIER; TG Therapeutics
Consulting or Advisory Role - Adaptive Biotechnologies; BeiGene; MorphoSys; Pharmacyclics; Seagen; SERVIER; TG Therapeutics
Speakers' Bureau - AstraZeneca; BeiGene; Kite, a Gilead company; Sanofi; Seagen; TG Therapeutics
Expert Testimony - Bayer
Travel, Accommodations, Expenses - AstraZeneca; Kite, a Gilead company; Sanofi; Seagen; TG Therapeutics
 
Nirav Niranjan Shah
Stock and Other Ownership Interests - Tundra Targeted Therapeutics
Consulting or Advisory Role - Incyte; Janssen Oncology; Juno/Bristol-Myers Sqibb; Kite, a Gilead company; Loxo/Lilly; Novartis; Seagen; TG Therapeutics
Research Funding - Adaptive Biotechnologies; Loxo/Lilly; Miltenyi Biotec
Travel, Accommodations, Expenses - Miltenyi Biotec